RA-004 (Red Arrow Therapeutics)

RA-004 is a preclinical-stage therapeutic candidate being developed by Red Arrow Therapeutics for the treatment of hyperactivated disorders of pregnancy. The drug utilizes the company's proprietary Nanopolymer Cytokine Micelle (NCM) platform technology, which involves the encapsulation of cytokine payloads within pH-responsive nanopolymers. This delivery system is designed to improve the pharmacokinetic profile of cytokines, enhancing their stability in systemic circulation and allowing for targeted release. While the specific cytokine payload and biological targets for RA-004 have not been publicly disclosed due to their confidential nature, the program is specifically engineered to address immune-mediated complications and hyperactivation during pregnancy.